NYSE:AGN - Allergan Stock Price, Price Target & More

Get Started

$154.00 +0.34 (+0.22 %)

(As of 05/25/2018 04:00 PM ET)

Previous Close$154.00

Today's Range$153.05 - $155.2699

52-Week Range$142.81 - $256.80

Volume1.27 million shs

Average Volume2.79 million shs

Market Capitalization$52.10 billion

P/E Ratio9.42

Dividend Yield1.87%

Beta1.17

About Allergan (NYSE:AGN)

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Receive AGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

SymbolNYSE:AGN

CUSIP01849010

Webwww.allergan.com

Phone862-261-7000

Debt

Debt-to-Equity Ratio0.36

Current Ratio1.10

Quick Ratio0.94

Price-To-Earnings

Trailing P/E Ratio9.42

Forward P/E Ratio9.61

P/E Growth1.1

Sales & Book Value

Annual Sales$15.94 billion

Price / Sales3.28

Cash Flow$40.2089 per share

Price / Cash3.83

Book Value$213.37 per share

Price / Book0.72

Profitability

EPS (Most Recent Fiscal Year)$16.35

Net Income$-4,125,500,000.00

Net Margins-11.94%

Return on Equity8.53%

Return on Assets5.00%

Miscellaneous

Employees17,800

Outstanding Shares339,060,000

Allergan (NYSE:AGN) Frequently Asked Questions

What is Allergan's stock symbol?

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

How often does Allergan pay dividends? What is the dividend yield for Allergan?

Allergan announced a quarterly dividend on Thursday, May 3rd. Investors of record on Friday, May 18th will be given a dividend of $0.72 per share on Friday, June 15th. This represents a $2.88 annualized dividend and a yield of 1.87%. The ex-dividend date of this dividend is Thursday, May 17th. View Allergan's Dividend History.

How will Allergan's stock buyback program work?

Allergan declared that its Board of Directors has authorized a share buyback program on Tuesday, September 26th 2017, which allows the company to repurchase $2,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 2.8% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company's board of directors believes its stock is undervalued.

How were Allergan's earnings last quarter?

Allergan (NYSE:AGN) released its earnings results on Monday, April, 30th. The company reported $3.74 earnings per share for the quarter, topping the Zacks' consensus estimate of $3.36 by $0.38. The firm earned $3.67 billion during the quarter, compared to analyst estimates of $3.59 billion. Allergan had a positive return on equity of 8.53% and a negative net margin of 11.94%. Allergan's revenue for the quarter was up 2.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.35 earnings per share. View Allergan's Earnings History.

When is Allergan's next earnings date?

Allergan is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Allergan.

What guidance has Allergan issued on next quarter's earnings?

Allergan issued an update on its FY18 earnings guidance on Monday, April, 30th. The company provided earnings per share (EPS) guidance of $15.65-16.25 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $15.66. The company issued revenue guidance of $15.15-15.35 billion, compared to the consensus revenue estimate of $15.24 billion.Allergan also updated its Q2 guidance to $4.00-4.20 EPS.

What price target have analysts set for AGN?

21 Wall Street analysts have issued 1-year price targets for Allergan's stock. Their forecasts range from $150.00 to $265.00. On average, they anticipate Allergan's stock price to reach $214.1616 in the next year. View Analyst Ratings for Allergan.

What are Wall Street analysts saying about Allergan stock?

Here are some recent quotes from research analysts about Allergan stock:

1. Mizuho analysts commented, "We Look for Long Term Outlook Color on the Call Rating Neutral Previous Rating No Change Price (4/27) $162.04 Price Target $185.00 Previous Price Target No Change 1Q:18 beat and 2Q:18 guidance above consensus: AGN reported $3.67B in revs and non-GAAP EPS of $3.74 vs. $3.60B and $3.36 FactSet consensus. The company had guided 1Q:18 to $3.5B-$3.6B in revs and EPS of $3.20- $3.40, and outperformed these metrics handily. The 1Q:18 beat was driven by lower OpEx and higher international sales. Allergan raised 2018 revenue guidance to $15.150B-$15.350B from $15.0B-$15.3B due to the prolonged durability of Restasis (already expected, in our view) and correspondingly raised its non-GAAP EPS range to $15.65-$16.25 from $15.25-$16.00 vs. FactSet consensus of $15.24B and $15.67, respectively, which we attribute in part to reduced share count. Allergan also introduced 2Q:18 guidance of $3.85B-$4.00B and $4.00-$4.20 non-GAAP EPS vs. $3.86B and." (4/30/2018)
2. Cantor Fitzgerald analysts commented, "This morning AGN reported a high quality 1Q18 EPS beat and raised its 2018 EPS guidance. This is clearly good news for the company, but we would note that a beat and raise was widely anticipated by the Street since AGN’s setup looked conservative heading into the year. Furthermore, if Restasis generics do not enter the market in 2018, we could see AGN continuing to beat its financial guidance throughout the year." (4/27/2018)
3. According to Zacks Investment Research, "Allergan’s products like Botox and Linzess and new products such as Viberzi, Namzaric and Vraylar support sales. It also boasts a strong branded pipeline. Biosimilars also represent significant opportunity. However, while we remain optimistic about the company’s growth prospects, it is facing potential loss of exclusivity for many products in 2018 including Namenda XR and Restasis. In October 2017, a Texas federal district court invalidated four of the six patents covering Restasis, potentially opening doors for early generic competition. Though Restasis patents are scheduled to expire in August 2024, a generic version may be launched as early as mid-2018. Also, new competition for key growth drivers, Restasis and Linzess, is an investor concern. Allergan’s shares underperformed the industry in the past six months. " (1/2/2018)

Who are some of Allergan's key competitors?

Some companies that are related to Allergan include Novartis (NVS), AbbVie (ABBV), Merck & Co. (MRK), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Bayer (BAYRY), GlaxoSmithKline (GSK), Sanofi (SNY), AstraZeneca (AZN), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Shire (SHPG), Zoetis (ZTS) and Vertex Pharmaceuticals (VRTX).

Who are Allergan's key executives?

Allergan's management team includes the folowing people:

Mr. Brenton L. Saunders, Chairman, Pres & CEO (Age 48)
Mr. William Meury, Exec. VP & Chief Commercial Officer (Age 50)
Mr. Matthew M. Walsh, Exec. VP & CFO (Age 51)
Mr. Wayne R. Swanton, Exec. VP of Global Operations (Age 50)
Mr. James C. D'Arecca, Chief Accounting Officer (Age 47)

Has Allergan been receiving favorable news coverage?

News articles about AGN stock have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Allergan earned a media sentiment score of 0.13 on Accern's scale. They also gave news stories about the company an impact score of 46.31 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Allergan's major shareholders?

Allergan's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.06%), Edgewood Management LLC (1.65%), Franklin Resources Inc. (1.59%), The Manufacturers Life Insurance Company (1.25%), Northern Trust Corp (1.21%) and Epoch Investment Partners Inc. (0.55%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh, Nesli Basgoz, Paul Bisaro and William Meury. View Institutional Ownership Trends for Allergan.

Which major investors are selling Allergan stock?

AGN stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Prudential Financial Inc., Levin Capital Strategies L.P., Neuberger Berman Group LLC, BlackRock Inc., Epoch Investment Partners Inc., TCW Group Inc. and Swiss National Bank. View Insider Buying and Selling for Allergan.

Which major investors are buying Allergan stock?

AGN stock was purchased by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Edgewood Management LLC, Toronto Dominion Bank, Ceredex Value Advisors LLC, Point72 Asset Management L.P., Canyon Capital Advisors LLC, Wells Fargo & Company MN and Morningstar Investment Services LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

How do I buy shares of Allergan?

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Allergan's stock price today?

One share of AGN stock can currently be purchased for approximately $154.00.

How big of a company is Allergan?

Allergan has a market capitalization of $52.10 billion and generates $15.94 billion in revenue each year. The company earns $-4,125,500,000.00 in net income (profit) each year or $16.35 on an earnings per share basis. Allergan employs 17,800 workers across the globe.

How can I contact Allergan?

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]

MarketBeat Community Rating for Allergan (AGN)

Community Ranking:		3.4 out of 5 ( )
Outperform Votes:		1,024 (Vote Outperform)
Underperform Votes:		468 (Vote Underperform)
Total Votes:		1,492

MarketBeat's community ratings are surveys of what our community members think about Allergan and other stocks. Vote "Outperform" if you believe AGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Allergan (NYSE:AGN) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

21 Wall Street analysts have issued ratings and price targets for Allergan in the last 12 months. Their average twelve-month price target is $214.1616, suggesting that the stock has a possible upside of 39.07%. The high price target for AGN is $265.00 and the low price target for AGN is $150.00. There are currently 6 hold ratings and 15 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.71	2.68	2.70	2.63
Ratings Breakdown:	0 Sell Rating(s) 6 Hold Rating(s) 15 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 7 Hold Rating(s) 15 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 6 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 7 Hold Rating(s) 12 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$214.1616	$220.1535	$225.53	$243.0588
Price Target Upside:	39.07% upside	37.69% upside	41.49% upside	40.07% upside

Allergan (NYSE:AGN) Consensus Price Target History

Price Target History for Allergan (NYSE:AGN)

Allergan (NYSE:AGN) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/17/2018	Wells Fargo & Co	Reiterated Rating	Buy		Low
5/7/2018	Cantor Fitzgerald	Reiterated Rating	Hold	$180.00	Low
5/3/2018	Credit Suisse Group	Lower Price Target	Outperform ➝ Outperform	$215.00 ➝ $213.00	Medium
5/1/2018	Bank of America	Lower Price Target	Buy ➝ Buy	$213.00 ➝ $209.00	Low
5/1/2018	Mizuho	Lower Price Target	Neutral	$150.00	Medium
5/1/2018	Deutsche Bank	Set Price Target	Buy	$210.00	Medium
4/24/2018	Citigroup	Reiterated Rating	Buy ➝ Buy	$220.00 ➝ $200.00	Medium
4/23/2018	Evercore ISI	Initiated Coverage	Outperform		Low
4/17/2018	Stifel Nicolaus	Initiated Coverage	Hold ➝ Hold	$192.00	Low
4/16/2018	Cowen	Set Price Target	Buy	$255.00	Low
3/26/2018	Leerink Swann	Reiterated Rating	Outperform		High
3/15/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$265.00	Low
3/14/2018	Royal Bank of Canada	Reiterated Rating	Buy	$213.00	Low
3/1/2018	Morgan Stanley	Lower Price Target	Overweight ➝ Overweight	$200.00 ➝ $181.00	High
2/23/2018	SunTrust Banks	Initiated Coverage	Buy ➝ Buy	$200.00	Low
1/29/2018	Barclays	Upgrade	Equal Weight ➝ Overweight	$220.00 ➝ $230.00	Low
1/10/2018	UBS	Set Price Target	Buy	$250.00	Medium
12/7/2017	Argus	Downgrade	Buy ➝ Hold	$256.80 ➝ $160.07	Low
10/18/2017	Edward Jones	Reiterated Rating	Buy ➝ Hold		N/A
10/18/2017	Sanford C. Bernstein	Set Price Target	Buy	$296.00 ➝ $252.00	N/A
10/13/2017	Piper Jaffray Companies	Set Price Target	Hold	$227.00	N/A
5/10/2017	Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$262.00	High
11/21/2016	William Blair	Reiterated Rating	Market Perform		N/A

(Data available from 5/26/2016 forward)

Allergan (NYSE:AGN) Earnings History and Estimates Chart

Earnings by Quarter for Allergan (NYSE:AGN)

Allergan (NYSE:AGN) Earnings Estimates

2018 EPS Consensus Estimate: $15.56
2019 EPS Consensus Estimate: $16.13

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	$3.37	$3.39	$3.38
Q2 2018	4	$3.17	$4.24	$3.86
Q3 2018	4	$3.65	$4.06	$3.87
Q4 2018	4	$4.16	$4.95	$4.45
Q1 2019	1	$3.73	$3.73	$3.73
Q2 2019	1	$4.01	$4.01	$4.01
Q3 2019	1	$4.10	$4.10	$4.10
Q4 2019	1	$4.29	$4.29	$4.29

Allergan (NYSE AGN) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/1/2018		$4.03					N/A
4/30/2018	Q1 2018	$3.36	$3.74	$3.5945 billion	$3.6721 billion	View	Listen
2/6/2018	Q4 2017	$4.74	$4.86	$4.2813 billion	$4.3261 billion	View	Listen
11/1/2017	Q3 2017	$4.06	$4.15	$4.0377 billion	$4.0340 billion	View	N/A
8/3/2017	Q2 2017	$3.95	$4.02	$3.9461 billion	$4.0074 billion	View	Listen
5/9/2017	Q1 2017	$3.32	$3.35	$3.5325 billion	$3.5730 billion	View	Listen
2/8/2017	Q416	$3.76	$3.90	$3.77 billion	$3.86 billion	View	Listen
11/2/2016	Q316	$3.57	$3.32	$3.73 billion	$3.62 billion	View	Listen
8/8/2016	Q216	$3.34	$3.35	$4.10 billion	$3.68 billion	View	Listen
5/10/2016	Q116	$3.03	$3.04	$3.97 billion	$3.80 billion	View	Listen
2/22/2016	Q415	$3.36	$3.41	$4.20 billion	$4.20 billion	View	Listen
11/4/2015	Q315	$3.20	$3.48	$5.71 billion	$4.10 billion	View	N/A
8/6/2015	Q215	$4.41	$4.41	$5.71 billion	$5.76 billion	View	N/A
5/11/2015	Q115	$3.84	$4.30	$4.04 billion	$4.23 billion	View	Listen
2/18/2015	Q414	$3.67	$3.91	$3.84 billion	$4.01 billion	View	N/A
11/5/2014	Q414	$1.83	$2.17	$1.9018 billion	$1.9105 billion	View	N/A
11/5/2014	Q314	$3.10	$3.19	$3.63 billion	$3.68 billion	View	N/A
8/5/2014	Q314	$1.76	$1.78	$1.78 billion	$1.79 billion	View	Listen
8/5/2014	Q214	$3.36	$3.42	$2.55 billion	$2.67 billion	View	N/A
7/21/2014	Q214	$1.44	$1.51	$1.77 billion	$1.83 billion	View	N/A
4/30/2014	Q114	$1.13	$1.18	$1.60 billion	$1.6460 billion	View	N/A
4/30/2014	Q114	$3.23	$3.49	$2.59 billion	$2.66 billion	View	Listen
2/20/2014	Q413	$3.05	$3.17	$2.68 billion	$2.78 billion	View	Listen
2/4/2014	Q413	$1.34	$1.12	$1.65 million	$1.66 million	View	N/A
10/29/2013	Q313	$1.20	$1.23	$1.53 billion	$1.23 billion	View	Listen
10/29/2013	Q313	$2.09	$2.09	$2.04 billion	$2.01 billion	View	Listen
7/31/2013	Q2 2013	$1.20	$1.22	$1.56 billion	$1.5977 billion	View	N/A
7/25/2013	Q2 2013	$2.00	$2.01	$1.9857 billion	$1.9898 billion	View	Listen
5/2/2013	Q1 2013	$1.86	$1.99	$1.97 billion	$1.90 billion	View	Listen
5/1/2013	Q1 2013	$0.96	$0.98	$1.44 billion	$1.46 billion	View	N/A
2/19/2013	Q4 2012	$1.53	$1.59	$1.74 million	$1.75 billion	View	Listen
2/5/2013	Q4 2012	$1.20	$1.15	$1.51 million	$1.48 million	View	N/A
10/30/2012	Q312	$1.04	$1.06	$1.43 billion	$1.39 billion	View	N/A
8/1/2012		$1.06	$1.07			View	N/A
5/2/2012		$0.87	$0.86			View	N/A
2/14/2012	Q4 2011	$1.75	$1.77			View	N/A
2/2/2012		$1.00	$1.00			View	N/A
10/26/2011		$0.90	$0.92			View	N/A
8/3/2011		$0.95	$0.96			View	N/A
7/26/2011	Q2 2011	$1.00	$1.01			View	N/A
5/4/2011		$0.74	$0.77			View	N/A
2/15/2011	Q4 2010	$0.93	$0.93			View	N/A
2/2/2011		$0.89	$0.88			View	N/A
11/4/2010	Q3 2010	$0.84	$0.85			View	N/A
8/5/2010	Q2 2010	$0.81	$0.83			View	N/A
5/10/2010	Q1 2010	$0.74	$0.63			View	N/A
2/23/2010	Q4 2009	$0.72	$0.85			View	N/A
11/4/2009	Q3 2009	$0.65	$0.66			View	N/A
7/29/2009	Q2 2009	$0.57	$0.61			View	N/A
4/30/2009	Q1 2009	$0.49	$0.58			View	N/A
2/19/2009	Q4 2008	$0.50	$0.53			View	N/A
10/29/2008	Q3 2008	$0.46	$0.48			View	N/A
8/6/2008	Q2 2008	$0.48	$0.48			View	N/A
5/1/2008	Q1 2008	$0.51	$0.55			View	N/A
2/20/2008	Q4 2007	$0.31	$0.35			View	N/A

(Earnings results data provided by Zacks Investment Research)

Allergan (NYSE:AGN) Dividend Information

Allergan pays an annual dividend of $2.88 per share, with a dividend yield of 1.87%. AGN's next quarterly dividend payment will be made on Friday, June 15. Allergan pays out 17.61% of its earnings out as a dividend.

Next Dividend:	6/15/2018
Annual Dividend:	$2.88
Dividend Yield:	1.87%
Dividend Growth:	141.00% (3 Year Average)
Payout Ratio(s):	17.61% (Trailing 12 Months of Earnings) 17.97% (Based on This Year's Estimates) 17.22% (Based on Next Year's Estimates) 7.16% (Based on Cash Flow)
Frequency:	Quarterly Dividend

Dividend Payments by Quarter for Allergan (NYSE:AGN)

Allergan (NYSE:AGN) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/3/2018	quarterly	$0.72	1.95%	5/17/2018	5/18/2018	6/15/2018
2/9/2018	quarterly	$0.72	1.71%	2/27/2018	2/28/2018	3/28/2018
10/27/2017	quarterly	$0.70	1.58%	11/16/2017	11/17/2017	12/15/2017
8/2/2017	Quarterly	$0.70	1.12%	8/16/2017	8/18/2017	9/15/2017
5/5/2017	quarterly	$0.70	0.01%	5/16/2017	5/18/2017	6/15/2017
11/2/2016	quarterly	$0.70		2/24/2017	2/28/2017	3/28/2017
2/4/2015	quarterly	$0.05	0.09%	2/5/2015	2/9/2015	3/20/2015
10/27/2014	quarterly	$0.05			11/20/2014	12/11/2014
7/28/2014	quarterly	$0.05	0.12%	8/13/2014	8/15/2014	9/5/2014
5/7/2014	quarterly	$0.05	0.12%	5/21/2014	5/23/2014	6/13/2014
2/5/2014	quarterly	$0.05	0.17%	2/26/2014	2/28/2014	3/21/2014
10/30/2013	quarterly	$0.05	0.22%	11/18/2013	11/20/2013	12/11/2013
7/31/2013	quarterly	$0.05	0.22%	8/20/2013	8/22/2013	9/12/2013
5/2/2013	quarterly	$0.05	0.2%	5/21/2013	5/23/2013	6/13/2013
2/6/2013	quarterly	$0.05	0.18%	2/26/2013	2/28/2013	3/21/2013

(Data available from 1/1/2013 forward)

Allergan (NYSE AGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.36%
Institutional Ownership Percentage: 79.57%

Insider Trading History for Allergan (NYSE:AGN)

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Allergan (NYSE AGN) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/17/2018	William Meury	EVP	Sell	24,425	$154.59	$3,775,860.75
3/15/2018	Maria Teresa Hilado	Insider	Buy	895	$167.39	$149,814.05
3/8/2018	Brent L. Saunders	CEO	Buy	3,300	$152.53	$503,349.00
3/8/2018	Matthew M. Walsh	CFO	Buy	1,000	$153.96	$153,960.00
3/5/2018	Joseph H. Boccuzi	Director	Buy	900	$143.42	$129,078.00
2/21/2018	Matthew M Walsh	CFO	Buy	2,000	$160.94	$321,880.00
2/14/2018	William Meury	Insider	Sell	58,879	$160.62	$9,457,144.98
12/7/2017	Chris W. Bodine	Director	Buy	3,030	$164.77	$499,253.10
12/6/2017	Brent L. Saunders	Chairman	Buy	4,600	$164.74	$757,804.00
12/5/2017	Christopher J. Coughlin	Director	Buy	10,000	$163.30	$1,633,000.00
12/1/2017	William Meury	Insider	Sell	11,807	$173.89	$2,053,119.23
5/18/2017	Nesli Basgoz	Director	Sell	1,889	$220.45	$416,430.05
3/2/2017	Paul Bisaro	Director	Sell	70,000	$246.68	$17,267,600.00	274,226
12/8/2016	Nesli Basgoz	Director	Sell	500	$188.72	$94,360.00
11/21/2016	Brent L. Saunders	CEO	Buy	5,250	$189.13	$992,932.50
11/11/2016	Maria Teresa Hilado	CFO	Buy	1,422	$210.64	$299,530.08	12,659
6/2/2016	Maria Teresa Hilado	CFO	Buy	661	$241.57	$159,677.77	11,957
5/11/2016	Nesli Basgoz	Director	Sell	459	$225.10	$103,320.90	5,242
12/7/2015	Nesli Basgoz	Director	Sell	2,300	$312.96	$719,808.00	4,062
8/24/2015	Paul Bisaro	Chairman	Buy	1,000	$297.42	$297,420.00	421,755
8/21/2015	Brent L Saunders	CEO	Buy	1,000	$301.94	$301,940.00	132,862
6/9/2015	Nesli Basgoz	Director	Sell	2,200	$297.89	$655,358.00
11/26/2014	William Meury	Insider	Sell	4,550	$269.14	$1,224,587.00
9/8/2014	Albert Paonessa III	Insider	Sell	6,642	$230.49	$1,530,914.58
4/22/2014	Scott Sherman	EVP	Sell	14,500	$155.82	$2,259,390.00	8,223
2/21/2014	Louis Lavigne, Jr.	Director	Sell	5,400	$125.79	$679,266.00	12,723
2/19/2014	Dawn Hudson	Director	Sell	4,200	$126.35	$530,670.00	11,600
2/19/2014	Jeffrey Edwards	CFO	Sell	38,900	$126.39	$4,916,571.00	16,591
2/19/2014	Raymond Diradoorian	EVP	Sell	23,000	$126.66	$2,913,180.00	6,401
2/18/2014	Scott Sherman	EVP	Sell	5,001	$125.74	$628,825.74	8,220
1/14/2014	Scott Whitcup	VP	Sell	42,000	$117.80	$4,947,600.00	17,327
12/27/2013	Julian Gangolli	VP	Sell	52,500	$110.05	$5,777,625.00
12/20/2013	Scott Whitcup	VP	Sell	33,000	$108.80	$3,590,400.00	17,327
10/15/2013	Trevor Jones	Director	Sell	2,000	$90.14	$180,280.00	7,142
9/16/2013	Albert Hummel	Director	Sell	6,200	$137.81	$854,422.00	82,776
9/16/2013	Trevor Jones	Director	Sell	2,000	$89.78	$179,560.00	8,142
9/4/2013	George Fred Wilkinson	Insider	Sell	16,749	$138.00	$2,311,362.00
9/4/2013	Jack Michelson	Director	Sell	6,064	$139.54	$846,170.56
8/29/2013	David Buchen	Insider	Sell	10,000	$135.56	$1,355,600.00	97,373
8/26/2013	Albert Hummel	Director	Sell	40,000	$134.44	$5,377,600.00	92,776
8/20/2013	Paul Bisaro	CEO	Sell	50,000	$135.30	$6,765,000.00	469,232
8/15/2013	Albert Paonessa III	Insider	Sell	5,476	$135.89	$744,133.64	33,812
8/15/2013	Trevor Jones	Director	Sell	2,000	$89.89	$179,780.00	9,142
8/14/2013	R Todd Joyce	CFO	Sell	15,000	$137.98	$2,069,700.00	80,470
8/13/2013	Albert Hummel	Director	Sell	10,000	$133.85	$1,338,500.00	132,776
8/12/2013	Cathy Klema	Director	Sell	1,667	$133.03	$221,761.01	19,608
8/12/2013	David Buchen	Insider	Sell	17,000	$133.03	$2,261,510.00	97,373
8/9/2013	Ronald Taylor	Director	Sell	5,000	$135.14	$675,700.00	27,942
8/6/2013	Jeffrey Edwards	CFO	Sell	69,200	$91.17	$6,308,964.00	16,871
8/5/2013	Charles Ebert	VP	Sell	8,244	$136.25	$1,123,245.00	19,970
8/5/2013	Michel Feldman	Director	Sell	10,000	$136.94	$1,369,400.00	12,941
8/2/2013	Robert Stewart	Insider	Sell	14,564	$136.02	$1,980,995.28	73,891
7/15/2013	Trevor M Jones	Director	Sell	2,000	$91.15	$182,300.00
6/17/2013	Trevor M Jones	Director	Sell	2,000	$101.25	$202,500.00
5/15/2013	Trevor M Jones	Director	Sell	2,000	$103.40	$206,800.00
5/9/2013	Jeffrey L Edwards	CFO	Sell	84,000	$103.49	$8,693,160.00
3/14/2013	Charles M Mayr	Insider	Sell	1,000	$91.77	$91,770.00
3/12/2013	Michael J Fedida	Director	Sell	8,000	$89.00	$712,000.00
11/26/2012	Trevor M Jones	Director	Sell	2,500	$91.30	$228,250.00
10/5/2012	David E I Pyott	CEO	Sell	616,300	$93.73	$57,765,799.00

(Data available from 1/1/2013 forward)

Allergan (NYSE AGN) News Headlines

Source:

Date	Headline
	Allergan Stock Down Since Q1 Earnings Report: Here's Why www.zacks.com - May 23 at 3:36 PM
	Allergan Stock Down Since Q1 Earnings Report: Here's Why finance.yahoo.com - May 23 at 3:36 PM
	Royal Caribbean, Allergan, Tyson Foods: 'Mad Money' Lightning Round www.thestreet.com - May 22 at 10:21 AM
	BRIEF-Allergan Exercises Option To Acquire Compound From Aptinyx Discovery Platform www.reuters.com - May 22 at 10:21 AM
	Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research ... www.prnewswire.com - May 22 at 10:21 AM
	Insider Selling: Allergan (AGN) EVP Sells 24,425 Shares of Stock www.americanbankingnews.com - May 21 at 7:16 PM
	Esmya Restriction In Europe Could Handcuff Allergan seekingalpha.com - May 21 at 10:31 AM
	Brainstorm Health: Ebola Vaccine, Obamacare Profitability, New Migraine Drug, David Tepper and Allergan fortune.com - May 19 at 10:22 AM
	Allergan (AGN) Could See Activism from David Tepper - Wells Fargo www.streetinsider.com - May 18 at 3:40 PM
	Top Research Reports for Walmart, AT&T & Novo Nordisk finance.yahoo.com - May 18 at 3:40 PM
	Appaloosa gets permission for activist stance with Allergan stake www.businessinsider.com - May 18 at 11:55 AM
	David Tepper now has the go-ahead to go full activist on Allergan if he wants to www.businessinsider.com - May 18 at 11:55 AM
	Facebook Directors Face New Challenges; Allergan Talks Botox Competitors--ICYMI www.thestreet.com - May 18 at 11:55 AM
	David Tepper gets US approval to take activist stance on Allergan, if he wants it www.cnbc.com - May 18 at 10:15 AM
	Allergan (AGN) vs. Its Peers Head to Head Survey www.americanbankingnews.com - May 17 at 9:18 PM
	Allergan's (AGN) "Buy" Rating Reiterated at Wells Fargo www.americanbankingnews.com - May 17 at 6:37 PM
	Charts of the Day: Walmart, Allergan, YouTube finance.yahoo.com - May 17 at 3:34 PM
	Teva's Generic Restasis Could Punish Allergan seekingalpha.com - May 17 at 10:48 AM
	Allergan plc. (AGN) Ex-Dividend Date Scheduled for May 17, 2018 www.nasdaq.com - May 16 at 3:40 PM
	Financial Contrast: Allergan (AGN) & Its Competitors www.americanbankingnews.com - May 15 at 1:39 PM
	Ex-Dividend Reminder: Duke Energy, Fortis and Allergan www.nasdaq.com - May 15 at 11:21 AM
	$3.90 Billion in Sales Expected for Allergan (AGN) This Quarter www.americanbankingnews.com - May 15 at 4:57 AM
	Will Mullets Bail Out Allergan? seekingalpha.com - May 14 at 11:46 AM
	Allergan (AGN) Given Consensus Rating of "Hold" by Analysts www.americanbankingnews.com - May 14 at 3:58 AM
	$4.03 EPS Expected for Allergan (AGN) This Quarter www.americanbankingnews.com - May 13 at 1:20 AM
	MARKETS: Biotech and pharma stocks could be the key to the market bull case finance.yahoo.com - May 12 at 3:35 PM
	Vraylar (Cariprazine; Gedeon Richter/Allergan/Mitsubishi Tanabe) Drug Outlook to 2026: Bipolar Disorder ... www.businesswire.com - May 11 at 3:46 PM
	Allergan: Could The Break-Up Be The Solution? seekingalpha.com - May 11 at 3:46 PM
	Allergan's Growth Is Really Dead seekingalpha.com - May 11 at 11:41 AM
	Allergan Forecasted to Earn Q2 2018 Earnings of $4.24 Per Share (AGN) www.americanbankingnews.com - May 11 at 9:50 AM
	Allergan Expected to Post Q3 2018 Earnings of $3.92 Per Share (AGN) www.americanbankingnews.com - May 10 at 7:58 AM
	How Companies Keep Most Earnings Calls So Incredibly Boring finance.yahoo.com - May 9 at 3:39 PM
	Morgan Stanley Turns Bearish On Ironwood Pharma, Lowers Linzess Sales Estimate finance.yahoo.com - May 9 at 3:39 PM
	Allergan: Sell That Volatility seekingalpha.com - May 8 at 3:33 PM
	Raleigh pharma ushers in new CEO from Allergan www.bizjournals.com - May 8 at 3:33 PM
	Allergan’s Valuations after Its 1Q18 Earnings finance.yahoo.com - May 7 at 3:40 PM
	Allergan (AGN) Receives "Hold" Rating from Cantor Fitzgerald www.americanbankingnews.com - May 7 at 12:57 PM
	Allergan (AGN) Downgraded by ValuEngine to Strong Sell www.americanbankingnews.com - May 5 at 1:50 AM
	Allergan is Oversold www.nasdaq.com - May 4 at 10:23 AM
	BRIEF-Ironwood And Allergan Announce Settlement With Aurobindo Pharma Resolving Linzess Patent Litigation www.reuters.com - May 4 at 10:23 AM
	Credit Suisse Group Cuts Allergan (AGN) Price Target to $213.00 www.americanbankingnews.com - May 4 at 12:17 AM
	Allergan (AGN) Announces Quarterly Dividend of $0.72 www.americanbankingnews.com - May 3 at 5:58 PM
	Technical Perspectives on Generic Drugs Stocks -- Allergan, Catalyst Pharma, Flexion Therapeutics, and Supernus ... www.prnewswire.com - May 3 at 10:23 AM
	Allergan: Too Much Focus On The Bad seekingalpha.com - May 2 at 3:36 PM
	Ironwood (IRWD) Incurs Loss in Q1, Announces Restructuring finance.yahoo.com - May 2 at 3:36 PM
	Allergan to Present Data from a Robust Mental Health Clinical Program at the American Psychiatric Association (APA ... www.prnewswire.com - May 2 at 10:26 AM
	Allergan Abandons Psoriasis Program, But Remains Steady With Acute Migraine Treatment seekingalpha.com - May 2 at 10:26 AM
	Allergan CEO Puts Split on Table in Urgent Review of Options www.bloomberg.com - May 2 at 10:26 AM
	Cantor Fitzgerald Equities Analysts Raise Earnings Estimates for Allergan (AGN) www.americanbankingnews.com - May 2 at 9:44 AM
	Q3 2018 EPS Estimates for Allergan Cut by William Blair (AGN) www.americanbankingnews.com - May 2 at 9:26 AM